Abstract
Objective. We evaluated the prognostic significance of CD44 isoform CD44 V6 in endometrial cancer.Method. Immunohistochemistry was used to determine the expression of CD44 V6 in 78 randomly selected endometrial cancer specimens.Results. CD44 V6 was detected in 53% (41/78) of the tumor samples. Clinicopathological evaluation revealed an inverse correlation with CD44 V6 expression and conventional poor prognosticators such as lower segment involvement, nuclear and structural grade, myometrial invasion, serosal involvement, lymph-vascular space invasion, and adnexal metastasis. Furthermore, the CD44 V6-negative group was found to be associated have a higher recurrence rate and a shorter disease-free survival.Conclusion. These findings indicate that absence of CD44 V6 expression in cases of endometrial cancer might be coupled with a more aggressive course.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
More From: Gynecologic Oncology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
